Foundation for Liver Research
31
1
1
26
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
6.5%
2 terminated/withdrawn out of 31 trials
92.9%
+6.4% vs industry average
42%
13 trials in Phase 3/4
8%
2 of 26 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (31)
Precision Nutrition to Improve Cardiometabolic Health With Dietary (Poly)Phenols
Role: collaborator
Immune Response in Patients With Hepatitis B and C Infection
Role: collaborator
Swiss Liver Venous Thrombosis Study
Role: collaborator
Study Comparing in Livertransplantation Recipients With Tacrolimus Alone Versus Tacrolimus&Sirolimus
Role: lead
High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV
Role: lead
Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS
Role: lead
Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer.
Role: lead
EndoRotor® Ablation of Barrett's Esophagus: Safety and Feasibility Study
Role: lead
PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients
Role: lead
Fully Covered or Partially Covered Stents in Malignant Esophageal Strictures
Role: lead
Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Treatment to Ncrease Sustained Response in CHB
Role: lead
Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients.
Role: lead
Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients
Role: lead
Genetic Study of Peginterferon Treatment in Hepatitis B Patients: The GIANT-B Study
Role: lead
Enzyme Suppletion in Exocrine Pancreatic Dysfunction
Role: lead
Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms
Role: lead
High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4
Role: lead
Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B
Role: lead
PEG-IFN in HBV Patients With Incomplete Response to NA
Role: lead
Pancreatic Enzyme Suppletion in Pancreatic Cancer
Role: lead